BeyondSpring Inc.

BYSI

KYG108301006

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 15:48:33 2024-05-14 EDT			5-day change	1st Jan Change
2.71 ^USD	+5.04%		+8.66%	+206.67%

04-29	North American Morning Briefing : Investors Brace -2-	DJ
04-22	North American Morning Briefing : Stock Futures -2-	DJ

BeyondSpring Inc. Announces the Resignation of Christine Ying Zhao from the Board of Directors, Effective January 1, 2023

December 30, 2022 at 04:30 pm

Ms. Christine Ying Zhao resigned from the Board of Directors of BeyondSpring Inc. (the Company),
effective January 1, 2023.

Latest news about BeyondSpring Inc.

North American Morning Briefing : Investors Brace -2-	04-29	DJ
North American Morning Briefing : Stock Futures -2-	04-22	DJ
North American Morning Briefing : Stock Futures -2-	04-15	DJ
BeyondSpring Says First Patient Dosed in Phase 2 Trial of Lung Cancer Combination Treatment	03-25	MT
Beyondspring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in A Phase 2 Investigator-Initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer	03-25	CI
BeyondSpring Inc. Announces Executive Changes	03-18	CI
Top Premarket Decliners	03-06	MT
BeyondSpring Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	02-02	CI
BeyondSpring Receives Non-Compliance Notice From Nasdaq	01-10	MT
BeyondSpring Receives Notification From Nasdaq for Breaching Minimum Bid Price Requirements	12-19	MT
Transcript : BeyondSpring Inc. - Special Call	11-07
BeyondSpring Inc. Announces New Data That Translates Preclinical Proof-Of-Concept to Clinical Evidence of Plinabulin?s Immunomodulating Activity	11-07	CI
BeyondSpring Inc. Announces Retirement of Yanbin Xie as Board of Director	23-07-14	CI
North American Morning Briefing : Traders Bet Data -2-	23-07-12	DJ
North American Morning Briefing : China Data -2-	23-07-05	DJ
North American Morning Briefing : Chip Stocks Take -2-	23-06-28	DJ
BeyondSpring Inc.(NasdaqCM:BYSI) added to Russell Microcap Value Index	23-06-23	CI
BeyondSpring Inc.(NasdaqCM:BYSI) added to Russell 3000E Value Index	23-06-23	CI
North American Morning Briefing: Investors Eye Powell Testimony	23-06-21	DJ
North American Morning Briefing : Focus Fixes on Fed, Powell	23-06-14	DJ
BeyondSpring Inc. Announces New Data from Phase 1 Investigator Initiated Study Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT	23-06-07	CI
North American Morning Briefing : China Trade Data -2-	23-06-07	DJ
North American Morning Briefing : Stock Futures -2-	23-05-31	DJ
North American Morning Briefing : Debt-Ceiling -2-	23-05-17	DJ
Baird Adjusts Price Target on BeyondSpring to $1.25 From $4, Maintains Outperform Rating	23-05-02	MT

BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for the debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.

Sector

Biotechnology & Medical Research

Calendar

2024-05-15 - R&D Day

More about the company

	1st Jan change	Capi.
BEYONDSPRING INC.	+206.67%	101M
VERTEX PHARMACEUTICALS INCORPORATED	+5.18%	111B
REGENERON PHARMACEUTICALS, INC.	+12.33%	105B
BIONTECH SE	-12.83%	22.34B
ARGENX SE	-3.70%	21.93B
GENMAB A/S	-6.03%	18.59B
WUXI APPTEC CO., LTD.	-35.21%	18.12B
BEIGENE, LTD.	-11.17%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+4.86%	13.7B
SAREPTA THERAPEUTICS, INC.	+36.59%	12.45B

Bio Therapeutic Drugs